Drug Trial Radar · NCT06041269
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Aug 31, 2023
Primary completion
Nov 29, 2024
Study completion May 30, 2025
Sponsor
- Lead sponsor
- AnaptysBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)
Conditions
- Rheumatoid Arthritis
Interventions
RosnilimabDrug
PD-1 agonist antibody
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from Baseline in 28-Joint Disease Activity Score based on CRP (DAS28-CRP) at Week 12Time frame: Baseline to Week 12
Locations
92 sites in 15 countries. Site status is shown where the registry gives one.
AnaptysBio Investigative Site 10-132
Flagstaff, Arizona
AnaptysBio Investigative Site 10-130
Glendale, Arizona
AnaptysBio Investigative Site 10-129
Phoenix, Arizona
AnaptysBio Investigative Site 10-131
Tucson, Arizona
AnaptysBio Investigative Site 10-105
Covina, California
Anaptys Bio Investigative Site 10-119
Rancho Mirage, California
AnaptysBio Investigative Site 10-113
San Diego, California
AnaptysBio Investigative Site 10-127
San Francisco, California
AnaptysBio Investigative Site 10-136
Temecula, California
AnaptysBio Investigative Site 10-133
Upland, California
AnaptysBio Investigative Site 10-112
Whitter, California
AnaptysBio Investigative Site 10-103
Aventura, Florida
AnaptysBio Investigative Site 10-141
Avon Park, Florida
AnaptysBio Investigative Site 10-118
Boynton Beach, Florida
AnaptysBio Investigative Site 10-125
Daytona Beach, Florida
AnaptysBio Investigative Site 10-122
Homestead, Florida
Anaptys Bio Investigative Site 10-142
Miami, Florida
AnaptysBio Investigative Site 10-140
Miami, Florida
AnaptysBio Investigative Site 10-102
Miami, Florida
AnaptysBio Investigative Site 10-124
Plantation, Florida
AnaptysBio Investigative Site 10-139
West Palm Beach, Florida
AnaptysBio Investigative Site 10-114
Chicago, Illinois
AnaptysBio Investigative Site 10-145
Monroe, Louisiana
AnaptysBio Investigative Site 10-143
Brookline, Massachusetts
AnaptysBio Investigative Site 10-116
Albuquerque, New Mexico
AnaptysBio Investigative Site 10-148
Smithfield, North Carolina
AnaptysBio Investigative Site 10-146
Middleburg Heights, Ohio
AnaptysBio Investigative Site 10-101
Jackson, Tennessee
AnaptysBio Investigative Site 10-120
Allen, Texas
AnaptysBio Investigative Site 10-107
Colleyville, Texas
AnaptysBio Investigative Site 10-123
Katy, Texas
AnaptysBio Investigative Site 10-108
Mesquite, Texas
AnaptysBio Investigative Site 10-110
Plano, Texas
AnaptysBio Investigative Site 10-106
The Woodlands, Texas
AnaptysBio Investigative Site 10-121
Tomball, Texas
AnaptysBio Investigative Site 10-117
Beckley, West Virginia
AnaptysBio Investigative Site 13-103
Antwerp, Belgium
AnaptysBio Investigative Site 13-102
Anderlecht, Brussels Capital, Belgium
AnaptysBio Investigative Site 13- 105
Liège, Liège, Belgium
AnaptysBio Investigative Site 13-104
Leuven, Vlaams-Braba, Belgium
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.